The EU Access Playbook Is Breaking. Here's Exactly Where.

AstraZeneca's CEO recently described the delay or cancellation of EU drug launches as a "mathematical necessity." He's right. But the word "mathematical" is doing a lot of work there — because it implies the calculation is fixed. It isn't. The variables have changed. And most access strategies are still solving for the old equation.

I've spent the better part of two decades sitting inside that equation — leading Health Economics and Outcomes Research (HEOR) at BMS through some of the most contested HTA environments in oncology, directing access and pricing strategy across the EU Cluster, then advising pharma and biotech leadership at IQVIA on launches where the stakes were high and the data were rarely clean. I've been in both rooms — the HEOR room and the pricing room. What I'm describing here isn't a theoretical failure. It's a pattern I've watched play out repeatedly, in different companies, across different assets, across different therapeutic areas. The shape of the problem is the same each time.

What the traditional model assumed

For decades, European launch strategy rested on a clean operating logic: sequence your markets to protect the International Reference Pricing (IRP) basket, generate your evidence to satisfy Health Technology Assessment (HTA), negotiate your price country by country. These were related decisions, but they could be managed sequentially — and in separate rooms. HEOR owned the evidence timeline. Pricing owned the IRP. Commercial owned the launch order. Each function optimised its own part of the problem, in the legitimate belief that someone else was holding the whole picture.

That belief was always partially a fiction. But the system held well enough that nobody had to confront it.

Three forces have now made that fiction untenable.

Force one: JCA moved the evidence deadline

The EU Joint Clinical Assessment has done something specific and underappreciated: it has moved the evidence standard to EU level and placed it upstream of national pricing negotiations. HTA assessment now happens once, centrally, before any individual market negotiation begins. The clinical evidence package is effectively locked before you know what Germany will pay, what France will accept, or what the Italian payer expects.

For companies running their evidence generation on a timeline calibrated to individual country submissions, JCA has moved the deadline forward by 12 to 18 months — often into a period when the data simply don't exist in the form the assessment requires.

Force two: MFN linked the European basket to the US price

Most Favored Nation pricing — now formalised through the GLOBE executive order mechanism — has done something structurally different: it has made European pricing decisions US pricing decisions. Every choice about where to launch first, what net price to accept in Germany, how you manage IRP leakage from Denmark or Switzerland — each of those now carries a direct implication for the $700 billion US market.

The consequences are already concrete and measurable. Amgen withdrew its cholesterol drug Repatha from Denmark, citing changed "global market dynamics" — widely linked to MFN pressure. Roche pulled Lunsumio from Switzerland's reimbursement list after negotiations with the federal health office broke down, avoiding publishing a price that could feed directly into the US reference calculation. According to GlobalData's Price Intelligence analysis, pharmaceutical launches across Europe fell 35% in the ten months following MFN's introduction — with the key EU reference basket countries (Denmark, France, Germany, Italy, Switzerland, the UK) disproportionately affected, as their prices feed directly into the US calculation.

I've sat in the room where the EU pricing corridor was set, and the US exposure wasn't in the model. I've also sat in the room where the US team discovered the European pricing decision after the fact. The gap between those two rooms is where value is being destroyed.

Force three: The reference baskets have shifted

The markets that once anchored a high price ceiling have changed their own rules. Germany moved to post-AMNOG net negotiated pricing in the reference basket — AMNOG being the reform that transformed Germany from a free-pricing market to a negotiated-price one — displacing the pre-AMNOG free pricing that made it a valuable anchor. Japan shifted to a lowest-price calculation across a smaller market basket. NICE — England's health technology assessment body — announced its first cost-effectiveness threshold change since 1999 alongside a US trade deal: a signal about the direction of travel that no one in pricing should treat as coincidental.

The IRP markets that used to establish a ceiling increasingly set a floor. The arithmetic of launch sequencing has inverted.

Where strategy breaks down

These three forces have done something structural. They've collapsed what were sequential decisions into a single, simultaneous decision that must be made earlier than the data comfortably support. The evidence plan is now also the pricing decision. The pricing decision is now also the sequencing decision. The sequencing decision is now also the US exposure decision.

Most organisations aren't structured to make this decision. HEOR owns evidence. Pricing owns IRP. Commercial owns launch sequencing. Each function is technically sound in its own lane. The problem is the gap between the lanes — and nobody owns the gap.

This isn't a failure of effort or intent. The problem isn't the quality of advice that organisations seek. It's that the advice arrives after the decisions have already been framed — and in a meeting room that only contains one part of the problem. The org structure was built for a world where these decisions could be made sequentially. That world no longer exists.

I've watched evidence plans get signed off without anyone in the room who owned the IRP implications of the launch sequence they assumed. I've watched launch sequencing decisions get made on an IRP logic that JCA had already invalidated. Each piece was technically defensible. Together, they produced a strategy that was coherent on paper and unworkable in practice.

The human cost

The people who bear the cost of that gap are patients — and they are never in the room.

The 578-day average delay between EMA approval and patient access is not an abstraction. For a patient with a late-stage cancer diagnosis, or a rare disease with few alternatives, 578 days is not a statistic. It is, in many cases, the difference between receiving a treatment and not receiving one. The unintended consequence of strategies built to protect pricing positions is that patients in smaller or lower-price markets — Denmark, Romania, Bulgaria — are increasingly the ones who simply don't get access at all. EU HTA reform was designed to improve equity. The MFN dynamic is, in practice, working against it.

What comes next

The mathematics are still solvable. But the access conversation has to begin earlier — at Phase 2, not pre-launch — and it has to happen in a room that doesn't currently exist in most organisations: one where evidence strategy, IRP, launch sequencing, and US commercial implications are treated as a single decision, made simultaneously, with imperfect data.

This isn't just an organisational question — for biotech, it's a commercial one. How a Phase 2 asset is positioned for EU access — its evidence design, its IRP sequencing logic, its exposure to the key EU reference basket — is increasingly a valuation input. Investors and partners asking about EU access aren't just asking about reimbursement; they're asking about the durability of the pricing position and the credibility of the launch plan. Getting that right at Phase 2 is no longer just a strategy question. It's a deal question.

The companies that close the gap won't do it by executing faster inside the old framework. They'll do it by changing who is in the room — and when the conversation starts.

I'm working through these questions with clients right now, and I don't think there are clean answers yet. I'd genuinely welcome perspectives from others navigating this — whether you're sitting in access, evidence, pricing, or on the commercial side. What's breaking down in your organisation, and where are you finding traction?